Ploutarchos Tzoulis
*The final, formatted version of the article will be published soon.
OPINION article
Front. Endocrinol.
Sec. Renal Endocrinology
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1453159
This article is part of the Research Topic Endocrine Regulation of Homeostasis of Water, Electrolytes and Organic Solutes View all articles
Empagliflozin: a wonder drug for the treatment of SIAD?
Provisionally accepted- Department of Metabolism and Experimental Therapeutics, Division of Medicine, University College London, London, United Kingdom
Keywords: empagliflozin, SGLT 2 inhibitor, Hyponatremia, SIAD(H), AVP
Received: 22 Jun 2024; Accepted: 20 Sep 2024.
Copyright: © 2024 Tzoulis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ploutarchos Tzoulis, Department of Metabolism and Experimental Therapeutics, Division of Medicine, University College London, London, United Kingdom
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.